摘要
目的探讨巴乐联合大黄蜇虫丸治疗慢性乙型肝炎肝纤维化,对肝纤维化的效果及抗肝纤维化的作用机制。方法210例慢性乙型肝炎肝纤维化患者被随机分为治疗组(n=110)和对照组(n=100),治疗组给予巴乐150mg,静脉注射,每日1次;大黄蜇虫丸6g,口服,每日2次。对照组用赛若金,疗程均为3个月。结果巴乐联合大黄蜇虫丸组显效率与对照组比较有统计学意义(P<0.01);在胆红素及转氨酸复常方面,该组亦优于对照组,差异有统计学意义(P<0.05)。两组治疗前、后肝纤维化指标检测结果,治疗组与对照组组比较差异有统计学意义(P<0.05)。结论巴乐联合大黄蜇虫丸对HA、PCⅢ、Ⅳ-C、LN的合成有抑制作用,可发挥抗肝纤维化的作用。
Objective To observe the effect of oxymatrine and Daihuangzhechong pill（DZP）on the indexes of liver function and fibrosis in patients with chronic hepatitis B,and to explore its possible anti-fibrosis effect and mechanism. Methods Two hundred and ten patients with chronic fibrosis were randomly divided into 2 groups：combined oxymatrine and DZP group and control group.The treatment group was given oxymatrine 100mg per day by intramuscular injection,and oral DZP 6g twice per day. The control group was administered IFN-α 1b 3million U by intramuscular injection. The therapeutic course was 3 months. Results At the end of the treatment, the curative effect in the treatment group was superior to the control group（P〈0.01）. Moreover the indexes of fiver functions（ALT,AST and Tbil） showed obvious improvement（P〈0.05）. Meanwhile liver fibrosis indexes in the treatment group declined significantly after 3 consecutive months, which were significantly lower than those before treatment（ P〈0.05） .Condusion Combined oxymatrine and DZP can improve the liver function and slow down or reverse liver fibrosis process with stable short-term effect.
出处
《重庆医学》
CAS
CSCD
2006年第14期1293-1294,共2页
Chongqing medicine
关键词
肝纤维化
巴乐
大黄蜇虫丸
liver fibrosis
oxymatrine
Daihuangzhechong pilI（DZP）
